Bimagrumab showed promising fat loss results in a mid-stage trial, but analysts raised concerns about safety and say more ...

Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

With the launch of Wegovy by Danish pharmaceutical giant Novo Nordisk and US major Eli Lilly’s Mounjaro already in ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare and Medicaid.

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...